Results 1 to 10 of about 15,307 (177)

Low-dose decitabine increases peripheral natural killer T (NKT)-like cell proportions in patients with chronic myeloid neoplasms [PDF]

Cancer Pathogenesis and Therapy
Decitabine is widely used in the treatment of chronic myeloid neoplasms, potentially through its immunomodulatory effects on CD8+ T cells and natural killer (NK) cells.
Zhanqiang Zhang, Yue Wang, Haojun Zhang, Jinjing Zhao, Zhili Yang, Xiaoqian Wang, Yujie Tang, Xuechun Lu, Rui Xu   +8 more
doaj   +2 more sources

Decitabine

Drugs, 2006
Decitabine is a hypomethylating agent. Its action in DNA leads to the reactivation of tumour suppressor genes and the subsequent differentiation of cancer cells. In a randomised, phase III trial in patients (n = 170) with myelodysplastic syndromes (MDS), intravenous decitabine (45 mg/m(2)/day for 3 consecutive days every 6 weeks) combined with ...
Kate, McKeage, Katherine F, Croom
europepmc   +3 more sources

Health-related quality of life of patients with acute myeloid leukemia and myelodysplastic syndromes/neoplasms treated with decitabine: a systematic literature review [PDF]

Annals of Hematology
Decitabine, including its new oral formulation (decitabine-cedazuridine, DEC-C), is commonly used in AML and MDS, particularly in older or unfit patients.
Laura Cannella, Adriano Venditti, Raffaele Palmieri, Serena Puglia, Mario Luppi, Massimo Breccia, Fabio Efficace   +6 more
doaj   +2 more sources

Comparison of maintenance with decitabine or chemotherapy in a real-world cohort of patients with acute myeloid leukemia [PDF]

Frontiers in Pharmacology
BackgroundThe objective of this real-world cohort study was to evaluate the efficacy and safety of decitabine versus conventional chemotherapy in the maintenance therapy (MT) of patients with acute myeloid leukemia (AML).MethodsData were collected from ...
Zhi-Feng Wei, Zhi-Feng Wei, Jia-Qi Yan, Jia-Qi Yan, Ye-Hui Tan, Ye-Hui Tan, Hai Lin, Hai Lin, Qiu-Ju Liu, Qiu-Ju Liu, Xiao-Liang Liu, Xiao-Liang Liu, Long Su, Long Su, Su-Jun Gao, Su-Jun Gao   +15 more
doaj   +2 more sources

DNA methylation landscape reveals LIN7A as a decitabine-responsive marker in patients with t(8;21) acute myeloid leukemia

Clinical Epigenetics, 2023
Background Despite its inconsistent response rate, decitabine, a demethylating agent, is often used as a non-intensive alternative therapeutic agent for acute myeloid leukemia (AML). It has been reported that relapsed/refractory AML patients with t(8;21)
Shujiao He, Yan Li, Xuanren Shi, Lei Wang, Diya Cai, Jingfeng Zhou, Li Yu   +6 more
doaj   +1 more source

Low-Dose Decitabine Augments the Activation and Anti-Tumor Immune Response of IFN-γ+ CD4+ T Cells Through Enhancing IκBα Degradation and NF-κB Activation

Frontiers in Cell and Developmental Biology, 2021
BackgroundCD4+ T cells play multiple roles in controlling tumor growth and increasing IFN-γ+ T-helper 1 cell population could promote cell-mediated anti-tumor immune response.
Xiang Li, Xiang Li, Liang Dong, Jiejie Liu, Chunmeng Wang, Yan Zhang, Qian Mei, Weidong Han, Ping Xie, Jing Nie   +9 more
doaj   +1 more source

Decitabine suspends human CD34+ cell differentiation and proliferation during lentiviral transduction. [PDF]

PLoS ONE, 2014
Efficient ex vivo transduction of hematopoietic stem cells (HSCs) is encumbered by differentiation which reduces engraftment. We hypothesized that inhibiting DNA methyltransferase with decitabine would block differentiation of transduced CD34+ cells ...
Naoya Uchida, Matthew M Hsieh, Charlotte Platner, Yogen Saunthararajah, John F Tisdale   +4 more
doaj   +1 more source

Reversible cardiomyopathy in a patient with chronic myelomonocytic leukemia treated with decitabine/cedazuridine: a case report

Cardio-Oncology, 2023
Background Hypomethylating agents (HMAs) have shown efficacy in the treatment of hematological malignancies and are indicated for the treatment of chronic myelomonocytic leukemia (CMML).
Ankur Sheel, Junu Bae, Ashlee Asada, Gregory A. Otterson, Ragavendra R. Baliga, Kristin L. Koenig   +5 more
doaj   +1 more source

Absence of early platelet increment in healthy mice during decitabine treatment

Scientific Reports, 2022
Treatment of myelodysplastic syndromes includes the administration of the hypomethylating agent decitabine. An early platelet response in decitabine-treated myelodysplastic syndrome patients is a predictor of overall survival. The effect of decitabine on
Juliane Baumann, Markus Spindler, Yannick Throm, Michael Lübbert, Markus Bender   +4 more
doaj   +1 more source

Gene Expression Profiles Identify Biomarkers of Resistance to Decitabine in Myelodysplastic Syndromes

Cells, 2021
Myelodysplastic syndrome (MDS) is a clonal hematopoietic stem cell disease characterized by inefficient hematopoiesis and the potential development of acute leukemia.
Seungyoun Kim, Dong-Yeop Shin, Dayeon Kim, Somi Oh, Junshik Hong, Inho Kim, Eunju Kim   +6 more
doaj   +1 more source